Could FFAR1 assist insulin secretion in type 2 diabetes?

摘要

In The Lancet, Charles Burant and colleagues4 report the glucose-lowering efficacy of a potential new type of insulin-releasing agent-an agonist of free fatty acid receptor 1 (FFAR1; also known as G-protein-coupled receptor 40 [GPR40]). In a 12-week phase 2 randomised double-blind controlled study of 426 patients with type 2 diabetes, Burant and co-workers found that the FFAR1 agonist TAK-875 (50-200 mg/day) produced a similar glucose-lowering effect (reduction of haemoglobin Alc by roughly 1% from a baseline of 8-4%) to that of the sulphonylurea glimepiride (2-4 mg/day).